Answers are grounded in this paper and cite their sources.
The current study shows that an SGLT2i or TZD could be a valid option as a fourth OAD for treatment of patients with T2D inadequately controlled with a triple combination of OADs.
No takes yet. Share an insight, caveat, or question.
Bae et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: